Imunon (Imunon) EBIT per Share : $-2.16 (TTM As of Mar. 2024)

View and export this data going back to 1999. Start your Free Trial

What is Imunon EBIT per Share?

Imunon's EBIT per Share for the three months ended in Mar. 2024 was $-0.52. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.16.

During the past 3 years, the average EBIT per Share Growth Rate was 35.50% per year. During the past 5 years, the average EBIT per Share Growth Rate was 35.30% per year. During the past 10 years, the average EBIT per Share Growth Rate was 41.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Imunon's EBIT per Share or its related term are showing as below:

IMNN' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -27 Med: 19.6 Max: 56.1
Current: 35.5

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Imunon was 56.10% per year. The lowest was -27.00% per year. And the median was 19.60% per year.

IMNN's 3-Year EBIT Growth Rate is ranked better than
85.29% of 1305 companies
in the Biotechnology industry
Industry Median: 3.6 vs IMNN: 35.50

Imunon's EBIT for the three months ended in Mar. 2024 was $-4.93 Mil.

Imunon EBIT per Share Historical Data

The historical data trend for Imunon's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imunon EBIT per Share Chart

Imunon Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-11.87

-10.35

-3.98

-4.54

-2.28

Imunon Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-0.66	-0.60	-0.37	-0.66	-0.52

Imunon EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Imunon's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-20.598	/	9.045
=	-2.28

Imunon's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-4.93	/	9.400
=	-0.52

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.16

Imunon (NAS:IMNN) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Imunon EBIT per Share Related Terms

Thank you for viewing the detailed overview of Imunon's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Imunon (Imunon) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imunon Inc (NAS:IMNN) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

CBO:Germany

Address

997 Lenox Drive, Suite 100, Lawrenceville, NJ, USA, 08648

Website

https://www.imunon.com

Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.

Executives

James E Dentzer	director	C/O AMICUS THERAPEUTICS, INC., 6 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Le Goff Corinne	director, officer: President and CEO	200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Michael H Tardugno	officer: Chief Executive Offier	10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046-2364
Frederick J. Fritz	director	C/O CELSION CORPORATION, 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046
Kardaras Constantine John	officer: Chief Accounting Officer	C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE100, LAWRENCEVILLE NJ 08648
Christine A Pellizzari	director	10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Stacy Lindborg	director	C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Donald P Braun	director	C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648
Alberto R Martinez	director	C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648
Jeffrey Wayne Church	officer: Chief Financial Officer
Robert W Hooper	director	C/O CELSION CORPORATION, 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046
Andreas Voss	director	C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648
Egwu, Inc. Fka Egen, Inc.	10 percent owner	601 GENOME WAY, SUITE 3400, HUNTSVILLE AL 35806
Khursheed Anwer	officer: Chief Scientific Officer	C/O CELSION CORPORATION, 997 LENOX DRVIE, SUITE 100, LAWRENCEVILLE NJ 08648
Gregory L Weaver	director	185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107